



JP 1642

TRANSMITTAL LETTER Applicant(s): Molly F. Kulesz-Martin		Attorney Docket No: RPP:135D US	
Serial No: 08/644,289	Filing Date: 05/10/96	Examiner: Y. Eyler	Art Unit: 1642
Invention: p53as PROTEIN AND ANTIBODY THEREFOR			

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is a/an: **SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (With Certification Under 37 C.F.R. Section 1.97(e)), PTO-1449 FORM AND ONE (1) REFERENCE**

IN THE ABOVE IDENTIFIED APPLICATION.

- ☒ No additional fee is required.
- ☐ A check in the amount of \$_____ is attached.
- ☐ Charge \$_____ to Deposit Account No. _____
A duplicate copy of this sheet is enclosed.
- ☒ Please charge any additional fees which may be due with respect to the accompanying papers, including those which may be due under 37 C.F.R. 1.16, 1.17, 1.18 and 1.20, or credit any overpayment to Deposit Account No. 04-1790.
A duplicate copy of this sheet is enclosed.

RECEIVED
JUL 12 1999
TECH CENTER 1600/2900

Respectfully submitted,

Dated: June 29, 1999

Michael L. Dunn
For Applicant(s)
Registration No. 25,330
P.O. Box 96
Newfane, New York 14108
Telephone: (716) 433-1661

MLD/csc

cc: M. DeLellis



#15172
072399

PATENT
RPP:135D US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Molly F. Kulesz-Martin

Art Unit: 1642


Serial No: 08/644,289

Filed: May 10, 1996

Examiner: Y. Eyler

For: p53as PROTEIN AND
ANTIBODY THEREFOR

I certify that this **SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT** is being deposited on June 29, 1999 with the U.S. Postal Service as first class mail addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231


Michael L. Dunn

Registration No. 25,330

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(With Certification Under 37 C.F.R. Section 1.97(e))

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The attached literature citation described below is being provided in compliance with Applicant's and their attorney's duty of candor and good faith under 37 C.F.R. 1.56, 1.97 and 1.98. A copy of the citation is recorded on the accompanying Form PTO-1449. It is requested that the reference cited herein be considered during further prosecution of this application.

A communication (European search report) from the European Patent Office issued April 27, 1999, disclosed the following reference which has not been previously cited by Applicants in an Information Disclosure Statement:

1.) EP 0 652 232 A1 (Health Research, Inc.)

The above reference is relevant due to the fact that it relates to p53 and/or p53as.

I hereby certify that each item of information contained in this Second Supplemental Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Dated: June 24, 1999

Respectfully submitted,



Michael L. Dunn
Attorney for Applicant(s)
Reg. No. 25,330
P.O. Box 96
Newfane, New York 14108
Telephone: (716) 433-1661

MLD/csc